Information Provided By: 
Fly News Breaks for February 20, 2020
BHC
Feb 20, 2020 | 09:32 EDT
Stifel analyst Annabel Samimy said Bausch Health maintained its "consistently solid performance" in Q4 with its eighth quarter of consecutive organic growth. While a combination of exceeding initial 2019 expectations and modest headwinds makes 2020 growth appear to pause, she thinks moderating loss of exclusivity in 2021 and 2022 should uncover underlying growth, said Samimy, who keeps a Buy rating and $35 price target on Bausch shares.
News For BHC From the Last 2 Days
